US Patent No. 10,113,200

GENES ASSOCIATED WITH DASATINIB SENSITIVITY


Patent No. 10,113,200
Issue Date October 30, 2018
Title Genes Associated With Dasatinib Sensitivity
Inventorship Daniel C. Danila, New York, NY (US)
Howard I. Scher, Tenafly, NJ (US)
Martin Fleisher, Glen Cove, NY (US)
Assignee MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)

Claim of US Patent No. 10,113,200

1. A method of selecting treatment with dasatinib for a prostate cancer patient comprising:(a) contacting RNA from a circulating tumor cell (CTC) obtained from the patient with a primer set for measuring expression of gene products of genes TACSTD2, SPAN8, COL3A 1, SPOCK1, SFN, KRT7, and S100A2, the set comprising a plurality of synthetic oligonucleotide primers, each of which is capable of hybridizing to an expression product of one of said genes such that the plurality of primers can detect the gene products of all of said genes to measure the relative expression of each of said genes in the CTC from the patient;
(b) contacting RNA from a known dasatinib-sensitive cell with a primer set for measuring expression of gene products of genes TACSTD2, TSPAN8, COL3A1, SPOCK1, SFN, KRT7, and S100A2, the set comprising a plurality of synthetic oligonucleotide primers, each of which is capable of hybridizing to an expression product of one of said genes such that the plurality of primers can detect the gene products of all of said genes to measure the relative expression of each of said genes in said known dasatinib-sensitive cell;
(c) comparing the expression level of said genes in the CTC from the patient with the expression level of said genes in a known dasatinib-sensitive cell;
(d) treating the patient with dasatinib when the expression level of the genes in the CTC is equal to or less than the expression level of the genes in a known dasatinib-sensitive cell.